MeSH term
Frequency | Condition_Probility | Animals | 39 | 0.0 |
Blotting, Western | 5 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Cell Line | 12 | 0.0 |
Cell Survival | 2 | 0.0 |
Cells, Cultured | 10 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Humans | 77 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Models, Biological | 2 | 0.0 |
Phosphorylation | 6 | 0.0 |
*Protein-Serine-Threonine Kinases | 2 | 0.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Rats | 12 | 0.0 |
Recombinant Proteins/metabolism | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 50 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 25 | 0.0 |
*Signal Transduction | 3 | 0.0 |
Time Factors | 6 | 0.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Mice | 19 | 0.0 |
Mice, Inbred C3H | 4 | 0.0 |
Mice, Nude | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Tumor Cells, Cultured | 16 | 0.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Binding Sites | 6 | 0.0 |
Carbohydrate Sequence | 2 | 0.0 |
Fibroblast Growth Factor 1/*metabolism | 4 | 36.0 |
Fibroblast Growth Factor 2/*metabolism | 2 | 3.0 |
Heparitin Sulfate/*metabolism | 2 | 6.0 |
Protein Binding | 8 | 0.0 |
Base Sequence | 14 | 0.0 |
Dimerization | 5 | 0.0 |
Ligands | 4 | 0.0 |
Protein Structure, Quaternary | 2 | 1.0 |
*Protein-Tyrosine Kinase | 5 | 1.0 |
Signal Transduction | 8 | 0.0 |
Cell Division/drug effects | 10 | 0.0 |
Female | 21 | 0.0 |
Fibroblast Growth Factor 1/*pharmacology | 7 | 36.0 |
Fibroblast Growth Factor 2/*pharmacology | 7 | 6.0 |
Fibroblast Growth Factors/*pharmacology | 3 | 6.0 |
Pregnancy | 3 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Reference Values | 2 | 0.0 |
Models, Molecular | 5 | 0.0 |
Molecular Sequence Data | 15 | 0.0 |
Cell-Free System | 2 | 0.0 |
Immunoblotting | 3 | 0.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Alternative Splicing | 4 | 0.0 |
Cell Division | 5 | 0.0 |
Cell Membrane/metabolism | 3 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
MAP Kinase Signaling System | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Protein Isoforms | 3 | 0.0 |
RNA/metabolism | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Transcription, Genetic | 6 | 0.0 |
Aged | 5 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Fibroblast Growth Factor 1/*genetics | 4 | 50.0 |
Gene Frequency | 2 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
CHO Cells | 3 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Exons | 3 | 0.0 |
Hamsters | 5 | 0.0 |
Heparin/metabolism | 2 | 1.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Transfection | 8 | 0.0 |
Fibroblast Growth Factors/*metabolism | 3 | 7.0 |
Male | 11 | 0.0 |
3T3 Cells | 3 | 0.0 |
Comparative Study | 6 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Temperature | 2 | 0.0 |
Heparin/*chemistry | 2 | 20.0 |
Protein Structure, Secondary | 2 | 0.0 |
Receptors, Fibroblast Growth Factor/*chemistry | 2 | 100.0 |
Fibroblast Growth Factor 1 | 11 | 39.0 |
Rabbits | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Xenopus laevis | 2 | 0.0 |
Adult | 7 | 0.0 |
Breast Neoplasms/*metabolism | 3 | 1.0 |
Fibroblast Growth Factor 2/metabolism | 4 | 4.0 |
Fibroblast Growth Factors/metabolism | 3 | 5.0 |
Gene Expression | 5 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Middle Aged | 7 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Receptors, Fibroblast Growth Factor/genetics/*metabolism | 3 | 8.0 |
Forskolin/pharmacology | 2 | 0.0 |
Phenotype | 3 | 0.0 |
Crystallography, X-Ray | 4 | 0.0 |
Protein Conformation | 4 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Receptors, Fibroblast Growth Factor/*biosynthesis/genetics | 3 | 27.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Tetrazolium Salts/pharmacology | 2 | 3.0 |
Cell Differentiation | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Signal Transduction/*physiology | 3 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Aorta | 2 | 1.0 |
Heparin/pharmacology | 2 | 0.0 |
Organ Culture Techniques | 2 | 0.0 |
Child | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
DNA Primers | 4 | 0.0 |
Fibroblast Growth Factors/genetics/*metabolism | 2 | 14.0 |
Chromosome Mapping | 3 | 0.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
*Chromosomes, Human, Pair 5 | 3 | 1.0 |
Sequence Tagged Sites | 2 | 0.0 |
Mitogens/metabolism | 2 | 8.0 |
Receptors, Fibroblast Growth Factor/*biosynthesis | 2 | 28.0 |
Radiation-Protective Agents/*pharmacology | 3 | 15.0 |
*Fibroblast Growth Factors | 3 | 3.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
*Chromosome Deletion | 2 | 0.0 |
Chromosomes, Human, Pair 5/*genetics | 2 | 2.0 |
Myelodysplastic Syndromes/*genetics | 3 | 4.0 |
DNA Primers/genetics | 2 | 0.0 |
Receptors, Fibroblast Growth Factor/*metabolism | 4 | 7.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Cell Differentiation/drug effects | 3 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Breast Neoplasms/*chemistry | 2 | 2.0 |
*Receptor Protein-Tyrosine Kinases | 2 | 3.0 |
Receptors, Fibroblast Growth Factor/analysis | 2 | 12.0 |
Fibroblast Growth Factor 1/*biosynthesis | 2 | 100.0 |
In Situ Hybridization | 2 | 0.0 |
Epithelium/metabolism | 3 | 0.0 |
PC12 Cells | 2 | 0.0 |
Cattle | 3 | 0.0 |
Cricetulus | 2 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Fibroblast Growth Factor 2/pharmacology | 2 | 0.0 |
NIH 3T3 Cells | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 2 | 0.0 |
Fibroblast Growth Factor 1/pharmacology | 2 | 8.0 |
Interleukin-1/*metabolism | 2 | 2.0 |
Mutation | 2 | 0.0 |
Fibroblast Growth Factor 1/metabolism | 3 | 42.0 |
Sequence Deletion | 2 | 0.0 |